Tizanidineb SR Pellets (CAS No: 64461-82-1) — Sustained Release Multiparticulates
Tizanidine HCl SR Pellets are sustained-release pharmaceutical pellets manufactured from Tizanidine Hydrochloride (C₉H₈ClN₅S·HCl, MW ≈290.2), a centrally-acting α2-adrenergic agonist used to manage spasticity from conditions such as multiple sclerosis and spinal cord injury. Swapnroop Drugs and Pharmaceuticals manufactures Tizanidine HCl SR Pellets at its WHO-GMP certified Aurangabad, Maharashtra facility for pharmaceutical formulators across India and export markets.
Formulation Approach
Tizanidine HCl is highly water-soluble (>20 mg/mL), which is a relevant formulation consideration when designing the rate-controlling functional coat needed to achieve a genuine extended-release profile rather than rapid dose-dumping; SR pellet systems for this molecule are typically built by drug-layering followed by a calibrated polymer coat.
Key Features
Applications
Why Choose Swapnroop for Tizanidine SR Pellets?
FAQs
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 1.0% |
| Water Content | NMT 2.0% |